Keyphrases
Adoptive Cell Therapy
20%
Biomarkers of Response
20%
Combination Immunotherapy
40%
Combination Therapy
20%
Conventional Chemotherapy
20%
CTLA-4 Inhibitors
20%
Gynecological Cancer
100%
Immune Checkpoint
20%
Immune Checkpoint Blockade
100%
Immune Recognition
20%
Immune Response
100%
Immunotherapy Strategy
40%
Monotherapy
20%
Novel Agents
20%
Novel Immunotherapy
20%
Overcoming Resistance
40%
PARP Inhibitor (PARPi)
20%
PD-1 Blockade
20%
Programmed Death-ligand 1 (PD-L1)
80%
Resistance Biomarkers
20%
Strategies to Overcome
20%
Targeted Agents
20%
Targeting Antibodies
20%
Tumor Cells
20%
Medicine and Dentistry
Antigen Recognition
20%
Biological Marker
20%
Cell Therapy
20%
Combination Therapy
20%
Cytotoxic T Lymphocyte Antigen 4 Antibody
20%
Female Genital Tract Cancer
100%
Hope
20%
Immune Checkpoint Blockade
100%
Immune Response
100%
Immunity
40%
Immunotherapy
40%
Monotherapy
20%
PARP Inhibitor
20%
Programmed Death-Ligand 1
60%
Tumor Cell
20%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
20%
Chemotherapy
20%
Combination Therapy
20%
Cytotoxic T Lymphocyte Antigen 4 Antibody
20%
Female Genital Tract Cancer
100%
Immunotherapy
40%
Monotherapy
20%
Neoplasm
20%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
20%